SAN DIEGO , June 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the addition of Exagen Inc. to MediNcrease Health Plans, LLC’s national provider network, providing enhanced care to their approximately 7.5 million

SAN DIEGO , May 26, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 42 nd Annual Growth Stock Conference , which takes place June 6-9, 2022 , in Chicago at the Loews Chicago Hotel .

SAN DIEGO , May 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE® Lupus are a contracted covered service with Alivio Health , providing enhanced care to their 150,000 members.

SAN DIEGO , May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Medicare Administrative Contractor (MAC) Noridian has provided pricing for AVISE ® Lupus. Noridian’s decision to price AVISE Lupus follows the approval by

Records in Ordering Healthcare Providers and Adopters, Set All-Time Record for AVISE® CTD Monthly Volume in March SAN DIEGO , May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended

SAN DIEGO , May 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a five-week awareness campaign to highlight important and impactful work being done to help those

SAN DIEGO , April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022 , after the market close on Wednesday, May 11, 2022 . Ron Rocca , Exagen’s President and Chief Executive

SAN DIEGO , April 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in Investor Summit Group’s Q2 Conference , which takes place May 3 rd - 4 th , 2022, in New York City at the Westin New York Grand Central

SAN DIEGO , March 30, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests have entered into an in-network agreement with Evolutions Healthcare Systems offering access to enhanced care to participating members.

SAN DIEGO , March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE ® tests will soon surpass 90 million lives as an in-network benefit for patients. Effective June 1, 2022 , AVISE test offerings become an